NCT06181084

A Study Comparing Different Formulations of LY3410738 in Healthy Adult Participants

A Pilot Study Comparing LY3410738 Capsule and Tablet Formulations and Effect of a Low-fat Meal and a Proton Pump Inhibitor on the Single-dose Pharmacokinetics of LY3410738 Tablets in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The main purpose of study is to compare different formulations of LY3410738 under fasting condition by looking at the amount of the study drug, LY3410738, that gets into the blood stream and how long it takes the body to get rid of it when given in healthy adult participants. The study will also access the effect of standard low-fat meal and esomeprazole (Proton Pump Inhibitor) on LY3410738. Safety and tolerability of LY3410738 will also be evaluated. For each participant, the total duration of the study will be 56 days for Groups 1 and 2 and up to 61 days for Groups 3 and 4, including screening.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LY3410738	Administered orally.
DRUG	Esomeprazole	Administered orally.

Timeline

• Start date: 2021-10-11
• Primary completion: 2022-04-28
• Completion: 2022-04-28
• First posted: 2023-12-26
• Last updated: 2023-12-26

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study